Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

University Hospital, Ghent80 enrolled

Overview

Evaluation of the effect of intrathecal administration of Baclofen on spasticity of cerebral palsy patients, by means of standardized and internationally accepted scales

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cerebral Palsy

Interventions

Administration of intrathecal baclofenDRUG

Eligibility

Sex: ALLMin age: 5 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CP patients with therapy-resistent spasticity * Patients with sufficient body weight in relation to the volume * Oral medication has failed: insufficient effect or too many side-effects * The patient and family understand the objectives of the treatment and accept those objectives * Informed Consent Exclusion Criteria: * Contra-indications for surgery (e.g. infection) * Hypersensitivity to oral Baclofen

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

Spasticity of patients after 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.